Synthaverse S.A. (SVE) - Total Liabilities
Based on the latest financial reports, Synthaverse S.A. (SVE) has total liabilities worth zł177.72 Million PLN (≈ $48.91 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SVE cash flow metrics to assess how effectively this company generates cash.
Synthaverse S.A. - Total Liabilities Trend (2010–2024)
This chart illustrates how Synthaverse S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check Synthaverse S.A. (SVE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Synthaverse S.A. Competitors by Total Liabilities
The table below lists competitors of Synthaverse S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Millie Seojae.
KQ:418470
|
Korea | ₩16.34 Billion |
|
Enex Co.Ltd
KO:011090
|
Korea | ₩86.81 Billion |
|
CBAK ENERGY TECH. NEW
F:B6JA
|
Germany | €316.70 Million |
|
Schwager
SN:SCHWAGER
|
Chile | CL$43.61 Billion |
|
Genetec Technology Bhd
KLSE:0104
|
Malaysia | RM132.62 Million |
|
Chosun Welding
KO:120030
|
Korea | ₩8.78 Billion |
|
AML3D Ltd
AU:AL3
|
Australia | AU$7.53 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
Taiwan | NT$1.19 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Synthaverse S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Synthaverse S.A. (SVE) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synthaverse S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synthaverse S.A. (2010–2024)
The table below shows the annual total liabilities of Synthaverse S.A. from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł177.15 Million ≈ $48.75 Million |
+15.59% |
| 2023-12-31 | zł153.26 Million ≈ $42.18 Million |
+166.37% |
| 2022-12-31 | zł57.54 Million ≈ $15.84 Million |
+36.11% |
| 2021-12-31 | zł42.27 Million ≈ $11.63 Million |
-12.94% |
| 2020-12-31 | zł48.55 Million ≈ $13.36 Million |
+0.65% |
| 2019-12-31 | zł48.24 Million ≈ $13.28 Million |
-13.63% |
| 2018-12-31 | zł55.85 Million ≈ $15.37 Million |
-11.65% |
| 2017-12-31 | zł63.22 Million ≈ $17.40 Million |
-43.32% |
| 2016-12-31 | zł111.53 Million ≈ $30.69 Million |
-23.69% |
| 2015-12-31 | zł146.16 Million ≈ $40.23 Million |
+165.36% |
| 2014-12-31 | zł55.08 Million ≈ $15.16 Million |
+40.44% |
| 2013-12-31 | zł39.22 Million ≈ $10.79 Million |
-20.57% |
| 2012-12-31 | zł49.38 Million ≈ $13.59 Million |
-12.13% |
| 2011-12-31 | zł56.19 Million ≈ $15.46 Million |
-5.41% |
| 2010-12-31 | zł59.41 Million ≈ $16.35 Million |
-- |
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more